Novo Nordisk CEO To Testify Sept. 24 On Ozempic, Wegovy Prices

By Gabrielle Wanneh / June 24, 2024 at 7:47 PM
Senate health committee chair Bernie Sanders (I-VT) has set Sept. 24 as the date for a high-profile hearing that will feature testimony from Novo Nordisk global CEO Lars Fruergaard Jørgensen on why the company has priced Ozempic and Wegovy dramatically higher in the United States than in other countries. The hearing announcement comes after Jørgensen willingly agreed to participate on a solo panel, prompting Sanders to drop his initial threat to subpoena the company’s U.S. president to appear. Sanders plans...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.